Weekly Funding Opportunities

[med-Research]

Mark Foundation for Cancer: Emerging Leader Award<https://themarkfoundation.org/emerging-leader-award/>
The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio. The grant amount is $250,000 per year for three (3) years totaling $750,000. Indirect costs are not to exceed 10% of direct costs and are included in total.
Eligibility particularities include:

  *   Applicants must be three to nine years from the start of an independent faculty research appointment as of December 31, 2021 (i.e., the official start date of the appointment must fall within the calendar years 2012-2018).
  *   This award is not intended to be the main source of funding for the applicant’s laboratory. Applicants must therefore demonstrate multi-year independent funding that sustains the central activities of the laboratory (e.g., at least one or two grants such as NIH/R01, NSF/CAREER, or equivalently substantial multi-year awards). Individual eligibility will be determined during the review stage.
Letter of intent due May 3, 2021. Med-RA deadline to receive draft documents: April 20.

Lung Cancer Research Foundation: Disparities in Lung Cancer<https://www.lungcancerresearchfoundation.org/wp-content/uploads/RFP-2021-Research-Grant-on-Disparities-in-Lung-Cancer.pdf>
While scientific advances steadily continue to reduce lung cancer incidence and deaths, the disease disproportionately affects various groups such as African Americans, Native Americans, low socioeconomic status populations and people from certain geographic locations. Despite progress to reduce the burden of tobacco, disparities in tobacco-related morbidity and mortality remain, and inequitable receipt of evidence-based lung cancer care continues to compound these disparities. We encourage applications on a wide variety of disparities-related topics including but not limited to the following:

  *   Gender disparities in lung cancer burden
  *   Causes and risk factors for lung cancer among never smokers
  *   Influence of social and biological risk factors on lung cancer outcomes, access to and use of care, and quality of care
  *   Genetic and gene-environment interactions
  *   Interactions and contributions of multiple factors (e.g. smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes
  *   Contribution of healthcare access and quality to disparities in outcomes
  *   Disparities related to other factors such as geography, socioeconomic status, and age
These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators.
Due May 7, 2021. Med-RA deadline to receive draft documents: April 26.

Gerber Foundation: Pediatric Research Grants<https://www.gerberfoundation.org/how-to-apply/>
The Gerber Foundation is dedicated to enhancing the quality of life of infants and young children, with an emphasis on children under three years of age. The foundation is accepting applications for research projects aimed at identifying solutions to common everyday issues and problems in the field of children’s health and nutrition. Of particular interest to the foundation are projects offering substantial promise of meaningful advances in prevention and treatment of disease and those with broad and general applicability.
Research program focus areas identified by the foundation include:

  *   Pediatric Health — Projects that promote health and prevent or treat disease. Of particular interest to the foundation are applied research projects focused on reducing the incidence of neonatal and early childhood illnesses, or those improving cognitive, social, and emotional aspects of development.
  *   Pediatric Nutrition — Projects that assure adequate nutrition to infants and young children, including applied research that evaluates the provision of specific nutrients and their related outcomes.
  *   Environmental Hazards (Nutrient Competitors) — Projects that document the impact of, or ameliorate the effects of, environmental hazards on the growth and development of infants and young children.
Major target areas for research include new diagnostic tools that may be more rapid, more specific, more sensitive, or less invasive; treatment regimens that are novel, less stressful or painful, more targeted, have fewer side effects, and/or provide optimal dosing; symptom relief; preventative measures; assessment of deficiencies or excesses (vitamins, minerals, drugs, etc.); and risk assessment tools or measures for environmental hazards, trauma, etc. The foundation is interested in supporting projects that will result in “new” information, treatments, or tools that result in a change in practice; it rarely funds projects that are focused on sharing current information with parents or caregivers. Grants of up to $350,000 over up to three years will be awarded. Novice researchers follow the same process as regular grants, are limited to no more than $20,000 in total funding, and need to apply under the guidance of a mentor.
Concept paper due May 15, 2021 and November 15, 2021. Med-RA deadline to receive draft documents for May 15 due date: May 3.

Chan Zuckerberg Initiative: Ancestry Networks for the Human Cell Atlas<https://chanzuckerberg.com/rfa/ancestry-networks-human-cell-atlas/>
To cure, prevent, or manage all diseases, scientific research should include people of all ancestries. To help advance that vision, the Chan Zuckerberg Initiative<https://chanzuckerberg.com/> (CZI) has launched a new funding opportunity<https://chanzuckerberg.com/rfa/ancestry-networks-human-cell-atlas> aimed at expanding the ancestral diversity of the samples in the Human Cell Atlas<https://www.humancellatlas.org/> (HCA), an international effort to map all cells in the human body as a foundational resource for understanding health and disease.
Diseases manifest differently in different people, and ancestry is one factor that impacts disease severity, outcome, and treatment. Individuals of European ancestry account for 80 percent<https://www.vox.com/science-and-health/2018/10/22/17983568/dna-tests-precision-medicine-genetics-gwas-diversity-all-of-us> of genomics data, and studies based on a narrow slice of ancestral background are often not generalizable to all people. To help fill these gaps in scientific knowledge, the Ancestry Networks for the Human Cell Atlas Request for Applications (RFA) will support teams of researchers to generate healthy, single-cell reference data from historically understudied populations.
The Ancestry Networks RFA builds off of CZI’s experience supporting the work of ten collaborative research teams that studied tissue samples from a diversity of populations<https://cziscience.medium.com/incentivizing-more-representative-research-2d610b7c19e8>, including people who are Black, Latinx, Asian, and Indigenous, as an initial step in addressing equal representation in the HCA. The new RFA will support collaborative networks of researchers for three-year projects. Teams should consist of at least three and up to ten principal investigators, including at least one computational biologist or data scientist and one expert in single-cell biology. Community-based participatory researchers should be involved in the collaboration to ensure that the research is attuned to the needs of and connected with the participating donor communities.
Ancestry Networks will collectively generate new tools, open source analysis methods, and openly available data from underrepresented donors across multiple tissue types and will provide valuable contributions to the HCA community. Example projects could include the generation of data from organs and tissues from a single or multiple ancestral groups; the development and sharing of tissue resources that will support standards, protocols, and tissue access to researchers; and the expansion of community engagement or donor recruitment programs and models.
Due May 25, 2021. Med-RA deadline to receive draft documents: May 12.

Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-021.html?utm_medium=email&utm_source=govdelivery>
The Transformative Research to Address Health Disparities and Advance Health Equity initiative is soliciting applications to support collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate health disparities and advance health equity. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in addressing health disparities and inequities.
Due May 28, 2021. Med-RA deadline to receive draft documents: May 17.

Louisa M. McGregor Ovarian Cancer Foundation (T.E.A.L.): Medical Research and Awareness Program Beneficiary<https://tealwalk.org/beneficiaries/>
The Tell Every Amazing Lady® About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation 2021 Medical Research Program offers funding in support of ovarian cancer research studies that are most aligned with their mission as determined by the T.E.A.L.® board of directors and scientific advisory board. The mission of T.E.A.L.® is to promote public awareness of and education about the signs, symptoms, and risk factors of ovarian cancer, provide support to survivors, and raise funds for research in order to find a cure. Budget: $15,000 per year; no IDC.
Due May 31, 2021. Med-RA deadline to receive draft documents: May 17.

Developing Digital Therapeutics for Substance Use Disorders (UG3 / UH3 Clinical Trial optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-183.html>
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD.The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.
Due August 4, 2021; December 6, 2021; August 4, 2022; December 6, 2022; August 4, 2023; December 6, 2023. Med-RA deadline to receive draft documents for August 4, 2021 due date: July 22.

NSF: Cognitive Neuroscience<https://www.google.com/url?q=https://www.nsf.gov/funding/pgm_summ.jsp?pims_id%3D5316%26WT.mc_id%3DUSNSF_39%26WT.mc_ev%3Dclick&sa=D&source=calendar&usd=2&usg=AOvVaw2SRSvQ8T1PgCajqDL3tsED>
The Cognitive Neuroscience Program seeks highly innovative proposals aimed at advancing a rigorous understanding of the neural mechanisms of human cognition. Central research topics for consideration by the program include attention, learning, memory, decision-making, language, social cognition, and emotions. Proposals with animal models are appropriate only if they include a comparative element with human subjects. Proposals focused on behavioral, clinical or molecular mechanisms will not be considered for this program. Additionally, proposals directed at understanding low-level sensorimotor processes or restricted to model-based simulations of neural data will not be considered, unless they are embedded in a cognitive question related to one of the central research topics listed above.
August 13, 2021; February11, 2022; and August 13, 2022. Med-RA deadline to receive draft documents for August 13, 2021 due date: August 2.

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-21-004.html>
This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.
Due August 24, 2021. Med-RA deadline to receive draft documents: August 11.

NSF / NIH: Science of Science Policy Approach to Analyzing and Innovating the Biomedical Research Enterprise (SCISIPBIO)<https://www.nsf.gov/pubs/2019/nsf19547/nsf19547.htm>
SCISIPBIO supports research that advances the scientific basis of science and innovation policy, with a focus on the biomedical sciences. Consistent with the SciSIP program, SCISIPBIO will fund the development of models, analytical tools, data and metrics that can inform science policy and the development of the scientific enterprise. SCISIPBIO welcomes individual and collaborative research projects and places a high priority on interdisciplinary research and on broadening participation.
Due September 9, 2021 and February 10, 2022. Med-RA deadline to receive draft documents for September 9 due date: August 26 (due to Labor Day holiday).

NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-015.html>
The NIH Director’s Pioneer Award Program<https://commonfund.nih.gov/pioneer> supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. The NIH Director’s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program<http://commonfund.nih.gov/highrisk/> of the NIH Common Fund<http://commonfund.nih.gov/>.
Due September 10, 2021. Med-RA deadline to receive draft documents: August 30.

Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Alzheimer’s Disease and Related Dementias (R25 – Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-010.html>
The objective of this FOA is to support short-term intensive courses or summer institutes for skills development on one of the three topics below; these have been identified by the National Institute on Aging as high priority needs in order to advance behavioral and social sciences research on AD/ADRD. This FOA particularly encourages development of courses that have a broad reach (i.e., beyond the applicant institution, and/or can be widely disseminated), as the goal of this FOA is to make the educational courses available to a wide range of investigators. Consideration should be given to course design that allows for virtual participation of both students and faculty, and plans for archiving and making publicly available didactic content including course curricula and videotaped lectures. In addition, courses should be designed to help recruit new and diverse research investigators into aging research and to provide participants with both formal and informal opportunities to interact with one another and with course faculty (in order to provide individual attention and to facilitate the formation of research collaborations). Finally, responsive applications will incorporate material on how the particular methodology or topic of focus can be employed to improve scientific understanding of the mechanisms underlying disparities in AD/ADRD or how they can be reduced.
Due October 4, 2021. Med-RA deadline to receive draft documents: September 21.

Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Aging (R25 – Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-009.html>
The goal of this Funding Opportunity Announcement (FOA) is to support short courses geared towards advancing selected priority topic areas identified by the National Institute on Aging (NIA) in order to advance research in the behavioral and social sciences. This FOA targets the following three priority research areas: 1) genomics for social scientists; 2) interdisciplinary social science research in aging; and 3) reproducibility in the social and behavioral sciences. Responsive applications will incorporate material on how the particular methodology or topic of focus can be employed to improve scientific understanding of the mechanisms underlying disparities in the aging process/aging outcomes or how such disparities can be reduced. Additional goals of the FOA are to help recruit new and diverse research investigators into aging research and to provide course participants with formal and informal opportunities to interact with one another and with course faculty (in order to provide individual attention and to facilitate the formation of research collaborations).
Due October 4, 2021. Med-RA deadline to receive draft documents: September 21.

Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed); Center for Tobacco Products<https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-004.html>
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) – Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey, the National Heart, Lung and Blood Institute’s Biologic Specimen and Data Repository Information Coordinating Center, and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. Other publicly available datasets would be considered, depending on analyses to be conducted. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA’s regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the FDA-CTP.
October 8, 2021; August 8, 2022; and March 8, 2023. Med-RA deadline to receive draft documents for October 8 due date: September 27.

Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-003.html>
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) – Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the US. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA’s regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the FDA-CTP.
Due October 8, 2021; August 8, 2022; and March 8, 2023. Med-RA deadline to receive draft documents for October 8 due date: September 27.

BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-135.html>
This Funding Opportunity Announcement (FOA) solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. As part of programs of building the informatics infrastructure for the BRAIN Initiative, the FOA supports several different, but related activities. These include modifying existing analysis and visualization tools to deal with BRAIN Initiative data and integrating different types of BRAIN Initiative datasets. Proposing the development of new tools to deal with BRAIN Initiative data is also permitted. The tools supported under this FOA will make use of relevant data standards and will be built so that they can be integrated into the data repositories, both of which are created in awards under the other FOAs of the BRAIN initiative informatics program. The tools must be user-friendly in accessing and analyzing data from appropriate data archives, and should analyze/visualize data without requiring users to download data. The tools should also allow data to be combined for analysis/visualization from multiple locations.
Due October 15, 2021; June 10, 2022; October 14, 2022; June 9, 2023; October 13, 2023; and June 7, 2024. Med-RA deadline to receive draft documents for October 15, 2021 due date: October 4.

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-190.html>
This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.
Due November 8, 2021; March 7, 2022; November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024. Med-RA deadline to receive draft documents for November 8, 2021 due date: October 26.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.



-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210409/fb2e0c96/attachment.html>